Described as currently operating in stealth mode and currently resident in JLab San Francisco, Soteria Biotherapeutics is working on development of next-generation T-cell therapies with the objective being provision of cancer treatment having improved efficacy and safety: engineering new control mechanisms for safer and more efficacious T-cell therapies. Therapies that harness the activity of T-cells have shown significant promise inhe treatment treating of hematologic malignancies. However, the efficacy of delivery has come at the cost of devastating side effects due to the fact that TCells can be activated too quickly and, in such conditions, trigger a severe systemic immune response. Control over CAR T-cells activation is clearly understood to be critical but currently available technologies have so far failed to address the problem. Soteria is organized around incorporating their switch technology into T-cell therapies for the treatment of cancer. Incorporation of activation switches will be critical for the maturation of these markets by reducing the risks associated with treatments, shortening inpatient stays, and enabling expansion into non-specialist hospitals.
